445 MARINE VIEW AVE SUITE 320, DEL MAR, CA
Financial Results, Press Release
Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
Other Events
Announces Commercial Product Availability of VIZZ in the United States
Announces US FDA Approval of VIZZ TM for the Treatment of Presbyopia
Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence